AgingResearch.NewsJoin free

PPARGPRO12ALAPOLYMORPHISM

There is 1 paper on PPARGPRO12ALAPOLYMORPHISM in aging research: 1 trial in people.

Gene

1 paper studies it1 finding

See all 1 papers on PPARGPRO12ALAPOLYMORPHISM

At a glance

The findings reach people, from one lab or study. 1 lab in 1 country.

“The gene*DHA interaction could not affect changes in P16, IL-6, or TNF-α mRNA expression or in telomerase activity in PBMC.”
DHA-enriched fish oil upregulates cyclin-dependent kinase inhibitor 2A (P16INK) expression and downregulates telomerase activity without modulating effects of PPARγ Pro12Ala polymorphism in type 2 diabetic patients: A randomized, double-blind, placebo-controlled clinical trialClinical nutrition (Edinburgh, Scotland)2016doi:10.1016/j.clnu.2016.12.007
Humans: a single group. Cells, worms or flies and mice: nothing yet.

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Includes the processes named after it and trials of drugs aimed at it.

  • 1 lab in 1 country
  • Funders: Iran National Science Foundation and 2 more
  • Human trial1

Effects

1

Response to DHA-enriched fish oil

no changein humans1

1 study

  1. PPARGPRO12ALAPOLYMORPHISM showed no clear effect on response to DHA-enriched fish oil in humans (type 2 diabetes).

    “The gene*DHA interaction could not affect changes in P16, IL-6, or TNF-α mRNA expression or in telomerase activity in PBMC.”

    Human trialtype 2 diabetesperipheral blood mononuclear cell8 weeksn = 72

    DHA-enriched fish oil upregulates cyclin-dependent kinase inhibitor 2A (P16INK) expression and downregulates telomerase activity without modulating effects of PPARγ Pro12Ala polymorphism in type 2 diabetic patients: A randomized, double-blind, placebo-controlled clinical trial

    Clinical nutrition (Edinburgh, Scotland)

Latest

Related